ImmuCell (NASDAQ:ICCC) Share Price Crosses Above 200-Day Moving Average – Here’s Why

ImmuCell Corporation (NASDAQ:ICCC) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.23 and traded as high as $6.29. ImmuCell shares last traded at $6.2350, with a volume of 13,385 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded ImmuCell from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ImmuCell has an average rating of “Sell”.

ImmuCell Trading Up 2.5%

The stock has a market cap of $56.40 million, a PE ratio of 32.82 and a beta of 0.29. The stock has a 50-day moving average price of $6.22 and a two-hundred day moving average price of $6.23. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.85 and a quick ratio of 1.99.

ImmuCell (NASDAQ:ICCC) last posted its earnings results on Thursday, August 14th. The biotechnology company reported $0.06 EPS for the quarter. The company had revenue of $6.45 million for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.

Institutional Trading of ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC lifted its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 71,852 shares of the biotechnology company’s stock after purchasing an additional 2,907 shares during the quarter. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.